On October 20, 2022 Biotec Pharmacon reported that Our collaborators at University College London (UCL) Biochemical Engineering Department have presented a poster on the use of M-SAN HQ for purification of lentivirus vectors for cell therapy applications (Press release, Biotec Pharmacon, OCT 20, 2022, View Source [SID1234622210]). The poster entitled: "Removal of contaminating DNA in downstream processing of lentiviral vectors" was presented at the 29th Annual European Society for Cell and Gene Therapy at the EICC in Edinburgh, Scotland on October 12th, 2022. First co-authors, Roman Labbé and Noor Mujahid showed that M-SAN HQ helps to clarify contaminating dsDNA with enzymatic digestion after an optimal period of 10 minutes incubation at 25 U/ml. The poster findings, in summary:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Significant differences were observed in the removal of dsDNA after enzymatic digestion compared to undigested samples
Lentivirus (LV) titre loss was observed but was attributed to bioprocessing conditions over the effect of nuclease digestion
Nuclease digestion led to a narrower particle distribution around 150 nm as measured by nanoparticle tracking assay (NTA)
Our M-SAN HQ is a leading nuclease for purification of viral vectors, with hundreds of satisfied customers in Cell and Gene Therapy and other biomanufacturing applications.